Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation

Angela S Koh, Bhaarathy Velmurugan, Fei Gao, Ru San Tan, Jia-Ing Wong, Louis L Y Teo, Bryan M H Keng, Serene J M Chua, Jian-Min Yuan, Woon-Puay Koh, Christine Cheung, Angela S Koh, Bhaarathy Velmurugan, Fei Gao, Ru San Tan, Jia-Ing Wong, Louis L Y Teo, Bryan M H Keng, Serene J M Chua, Jian-Min Yuan, Woon-Puay Koh, Christine Cheung

Abstract

Background: SuPAR is a biomarker that reflects the level of immune activation. As inflammation plays an important role in the ageing process of the cardiovascular system, we hypothesized that suPAR might be a useful predictive biomarker of the ageing heart.

Methods: We performed conventional and tissue Doppler echocardiography and measured plasma suPAR levels.

Results: We studied community adults (n=120, 37.5% female) (mean age: 70.3±9.3 years) without known cardiovascular disease (CVD). Participants with impaired myocardial relaxation were older (84% vs 59% were aged ≥71 years, p=0.002), with more diabetes mellitus (27% vs 11%, p=0.034). SuPAR levels were higher among participants with impaired myocardial relaxation (3.9 ng/ml vs 3.0 ng/ml, p=0.015). At the univariate level, older age (OR 3.6; 95%CI 1.6, 8.5; p=0.003), diabetes mellitus (OR 3.04; 95%CI 1.1, 8.8; p=0.04), systolic blood pressure (OR 1.03; 95%CI 1.001, 1.1; p=0.041) and suPAR levels ≥3.00ng/ml (OR 3.4; 95%CI 1.16, 7.4; p=0.002) were associated with impaired myocardial relaxation. In multivariable regression analysis, only older age (OR 2.8; 95%CI 1.1, 6.7; p=0.026) and suPAR (OR 2.7; 95%CI 1.2, 6.1; p=0.018) remained independently associated with impaired myocardial relaxation. Receiver operating characteristics (ROC) curve analysis revealed an area under the curve (AUC) value of 0.63 (95% CI 0.54, 0.71) for model that included age alone. Addition of suPAR significantly increased AUC value to 0.70 (95%CI 0.60, 0.79), which was significantly larger than the model with age alone (p=0.016).

Conclusion: We demonstrate additional ability of suPAR, over age, to predict impaired myocardial relaxation.

Trial registration: ClinicalTrials.gov Identifier: NCT02791139 (Registered May 31, 2016).

Keywords: Ageing; Biomarker; Cardiac function; Cardiovascular disease; Elderly; Soluble urokinase plasminogen activator receptor.

Conflict of interest statement

Ethics approval and consent to participate

Written informed consent was obtained from participants upon enrolment. The SingHealth Centralised Institutional Review Board had approved the study protocol (2014/628/C).

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Receiver operating characteristic (ROC) curves for discriminating between preserved myocardial function and impaired myocardial function using age (blue line) or age plus suPAR (red line)

References

    1. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a "set up" for vascular disease. Circulation. 2003;107(1):139–146. doi: 10.1161/01.CIR.0000048892.83521.58.
    1. Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part III: cellular and molecular clues to heart and arterial aging. Circulation. 2003;107(3):490–497. doi: 10.1161/01.CIR.0000048894.99865.02.
    1. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part II: the aging heart in health: links to heart disease. Circulation. 2003;107(2):346–354. doi: 10.1161/01.CIR.0000048893.62841.F7.
    1. Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015;116(7):1254–1268. doi: 10.1161/CIRCRESAHA.116.302317.
    1. Lakatta EG. Cardiovascular regulatory mechanisms in advanced age. Physiol Rev. 1993;73(2):413–467.
    1. Riisbro R, Christensen IJ, Hogdall C, Brunner N, Hogdall E. Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers. 2001;16(4):233–239.
    1. Persson M, Engstrom G, Bjorkbacka H, Hedblad B. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmo diet and cancer study. Atherosclerosis. 2012;220(2):502–505. doi: 10.1016/j.atherosclerosis.2011.10.039.
    1. Koller L, Stojkovic S, Richter B, Sulzgruber P, Potolidis C, Liebhart F, et al. Soluble Urokinase-type plasminogen activator receptor improves risk prediction in patients with chronic heart failure. JACC Heart Fail. 2017;5(4):268–277. doi: 10.1016/j.jchf.2016.12.008.
    1. Lyngbaek S, Marott JL, Moller DV, Christiansen M, Iversen KK, Clemmensen PM, et al. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention. Am J Cardiol. 2012;110(12):1756–1763. doi: 10.1016/j.amjcard.2012.08.008.
    1. Pliyev BK. Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87) Mol Cell Biochem. 2009;321(1–2):111–122. doi: 10.1007/s11010-008-9925-z.
    1. Hankin JH, Stram DO, Arakawa K, Park S, Low SH, Lee HP, et al. Singapore Chinese health study: development, validation, and calibration of the quantitative food frequency questionnaire. Nutr Cancer. 2001;39(2):187–195. doi: 10.1207/S15327914nc392_5.
    1. Theilade S, Rossing P, Eugen-Olsen J, Jensen JS, Jensen MT. suPAR level is associated with myocardial impairment assessed with advanced echocardiography in patients with type 1 diabetes with normal ejection fraction and without known heart disease or end-stage renal disease. Eur J Endocrinol. 2016;174(6):745–753. doi: 10.1530/EJE-15-0986.
    1. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010;268(3):296–308. doi: 10.1111/j.1365-2796.2010.02252.x.
    1. Parish RC, Evans JD. Inflammation in chronic heart failure. Ann Pharmacother. 2008;42(7):1002–1016. doi: 10.1345/aph.1K272.
    1. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3(12):932–943. doi: 10.1038/nrm977.

Source: PubMed

3
Subscribe